Takayasu Arteritis — Research Summary
Printed from RareWays (rareways.com.au) on 12 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Serum calprotectin as a biomarker for large vessel vasculitis: a multicenter cross-sectional study.
Çöpür Sidar et al. — International immunopharmacology (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42541830/
- 2.
Immune checkpoint inhibitor-associated aortitis and classical large-vessel vasculitis: Clinical characterization and pharmacovigilance analysis using FAERS.
Guo Qian et al. — Seminars in arthritis and rheumatism (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42623759/
- 3.
Bilateral Pulmonary Arterial Involvement in Takayasu Arteritis.
Inoue Yuta et al. — Balkan medical journal (8 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42706897/
- 4.
Collateral vessels supplying blood to the brain and the entire upper body in a patient with Takayasu arteritis.
Oki Naohiko et al. — Journal of vascular surgery (8 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42710602/
- 5.
Diagnostic performance of [18F]FDG PET/CT in large vessel vasculitis management: an umbrella review.
Del Grande Maria et al. — The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42411928/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Takayasu Arteritis
Takayasu arteritis is a rare form of vasculitis in which the immune system inflames the aorta and its main branches, causing the vessel walls to thicken and narrow. It often begins in younger women and can lead to weak or absent pulses, limb pain on exertion, dizziness and high blood pressure. Treatment usually involves steroids and other immune-suppressing medicines, with imaging to monitor the arteries and surgery or stenting in some cases.
Most Recent Research
OBJECTIVE: Large vessel vasculitis (LVV), namely Takayasu arteritis (TAK) and giant cell arteritis (GCA), is the most common type of primary vasculitis affecting adult patients with significant and potentially debilitating consequences. Even though C-reactive protein (CRP) and erythrocyte sedimentation rate are widely utilized biochemical markers for disease activity among LVV patients, such biomarkers are not without major drawbacks, especially with the more widespread use of anti-interleukin-6 based therapies. METHODS: We have conducted a multicentered, cross-sectional cohort study involving a total of 149 LVV patients with 183 clinical visits from seven tertiary care centers with specialized rheumatology clinics. RESULTS: A total of 42 GCA and 107 TAK patients with a mean age of 51.2 (±18.04) years and female predominance have been included in our study while 14.1% of the patients were classified as in active disease state. We have failed to demonstrate a statistically significant association between serum calprotectin levels and disease activity states among LVV patients 1.65 (1.15-2.08) vs 1.26 (0.65-1.81) μg/mL, p = 0.077), the GCA subgroup (1.65 (1.47-1.70) vs 0.88 (0.59-1.75) μg/mL, p = 0.136), or the TAK subgroup (1.73 (0.86-2.08) vs 1.32 (0.92-1.77) μg/mL, p = 0.466). In contrast, CRP was significantly higher in active disease in the overall cohort (7.13 (0.56-21.70) vs 2.60 (0.84-6.58) mg/L, p = 0.044) and in the GCA subgroup (14.75 (6.97-19.80) vs 1.44 (0.50-6.00) mg/L, p = 0.039), but not in the TAK subgroup (p = 0.162). CONCLUSION: Our large-scale multicentered cohort study has failed to demonstrate superiority of serum calprotectin assay in the assessment of disease activity among LVV patients. With the growing use of numerous biological agents in LVV treatment, the need for a reliable biomarker with strong discriminative power still continues.
Common Questions
What is Takayasu Arteritis?
Takayasu arteritis is a rare form of vasculitis in which the immune system inflames the aorta and its main branches, causing the vessel walls to thicken and narrow. It often begins in younger women and can lead to weak or absent pulses, limb pain on exertion, dizziness and high blood pressure. Treatment usually involves steroids and other immune-suppressing medicines, with imaging to monitor the arteries and surgery or stenting in some cases.
How many clinical trials are available for Takayasu Arteritis?
RareWays currently indexes 58 clinical trials for Takayasu Arteritis, of which 19 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Takayasu Arteritis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Takayasu Arteritis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.